|Bid||3.1200 x N/A|
|Ask||3.2350 x N/A|
|Day's Range||3.1050 - 3.3150|
|52 Week Range||3.1000 - 8.7100|
|Beta (5Y Monthly)||0.89|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 29, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||8.88|
Subscribe to Yahoo Finance Plus to view Fair Value for NANOFH.HE
The positive momentum continues. A quarterly record of eight new non-GMP projects with seven different customers signed. Revenue grew by 174%, the number of employees by 49%, while the total operating costs grew by 27%. The gross margin rose to 92%. Significant productivity gains and economies of scale will enable continued slower growth in costs while rapidly expanding our manufacturing capacity. All near-term 2022 and mid-term 2025 targets are on track.
Nanoform successfully completes new share issue raising EUR 25 million to prepare for GMP manufacturing in the USA
The strong momentum continues: all near-term business targets for 2021 achieved, rapid customer project intake accelerating, commercial team in Europe expanded, more line capacity added, ISMS certificate received, and a new near-term business target introduced: "Biologics pilot line for GMP in 2022".